Clinical trials: Prostate-Specific Antigen, open to volunteers
Metastatic Prostate Cancer
Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer
The purpose of this clinical trial is to determine the anti-tumor activity of talazoparib plus enzalutamide as first line treatment for metastatic castration resistant prostate cancer (mCRPC) in participants whose disease has…
- Trial name
- TEAM PC (NCT06582628)
- Testing
- Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule
- Where
- 19 sites in France, Spain
- Volunteers
- 78 people
- Sponsor
- Fundacion Oncosur
Prostate Cancer, Brachytherapy
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
PRO-BOOST-N is a prospective, multicenter, randomized phase II/III clinical trial for patients with prostate cancer and pelvic lymph node involvement (cN1M0) confirmed by PSMA PET/CT, without distant metastatic disease.
- Conditions
- Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT), Dose Escalation: Solid Tumors
- Trial name
- PRO-BOOST-N (NCT07426094)
- Testing
- Ultrahypofractionated Whole-Pelvis Radiotherapy, SBRT-Based Prostate Radiotherapy (No Boost), Ablative Prostate Boost
- Where
- Poland
- Volunteers
- 600 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Prostate Cancer
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance.
- Trial name
- NCT06600698
- Testing
- INM176
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Milton S. Hershey Medical Center
Prostate Cancer, Recurrent Prostate Cancer
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression in patients with prostate cancer belonging to the intermediate unfavorable or high risk group, who have low…
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent
- Trial name
- NCT07593079
- Testing
- Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Safety and Efficacy of OTL78
This is a trial to assess the accuracy of an imaging agent, PSMA targeted fluorescent dye OTL78 (zopocianine), in combination with Near InfraRed (NIR) fluorescent imaging, to improve the detection of malignant (growing in an…
- Trial name
- NCT07725523
- Testing
- 0.06 mg/kg ZOPOCIANINE given 1-7 days prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Clinton Bahler
Prostate Cancer
Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.
A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA <0.70 ng/ml)…
- Trial name
- PROPER2 (NCT04858880)
- Testing
- Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.
- Where
- 3 sites in Sweden
- Volunteers
- 374 people
- Sponsor
- Lund University Hospital
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer…
- Trial name
- TulmiSTAR-02 (NCT07190300)
- Testing
- Tulmimetostat, Darolutamide, Abiraterone
- Where
- 31 sites in United States, Australia and 12 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T
This study is a phase I dose escalation clinical trial aims to evaluate 161Tb-PSMA-I\&T, a new generation prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) using Terbium-161 to replace Lutetium-177, its…
- Trial name
- NCT07621692
- Testing
- 161Tb-PSMA-I&T
- Where
- 2 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
To qualitatively determine the imaging performance of PET-CT imaging subsystem of the RefleXion X1 System Device in patients undergoing standard-of-care (SOC) [68Ga]-PSMA-11 PET-CT using Illuccix on the same day.
- Trial name
- NCT06353321
- Testing
- PET-CT imaging subsystem of the RefleXion X1 System Device
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
This study will determine the safe initial injected activity of the radioligand therapy 177Lu-HTK03170 for the measurement of dosimetry and initiation of treatment in subjects with PSMA-positive, metastatic castrate resistant…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer
- Trial name
- NCT05570994
- Testing
- 177Lu HTK03170, 68Ga-HTK03149
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial…
- Trial name
- Visioning III (NCT07762911)
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- PAnTHA (NCT06217822)
- Testing
- 225Ac-PSMA-Trillium (BAY3563254)
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Prostate Cancer
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.
- Trial name
- ESCAPE (NCT05948657)
- Testing
- PSMA-PET CT
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm.
- Trial name
- ProScreen (NCT03423303)
- Testing
- Prostate cancer screening
- Where
- 2 sites in Finland
- Volunteers
- 17,400 people, healthy volunteers welcome
- Sponsor
- Tampere University
Advanced Prostate Cancer
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease…
- Trial name
- NCT06335914
- Testing
- Ga 68 PSMA-11 PET, 18F-DCFPyL PET, FDG PET
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
This prospective, single-center diagnostic accuracy study will compare mpMRI and PSMA-PET for the detection of clinically significant prostate cancer in patients with prostate imaging reporting and data System (PI-RADS) ≥4…
- Trial name
- PRIME-TZ (NCT07892378)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI), 18F-PSMA-1007 PET, Prostate Biopsy
- Where
- Argentina
- Volunteers
- 65 people
- Sponsor
- Sanatorio Privado San Geronimo
PSMA Positive Tumors or Tumor Tissues
PSMA-specific CAR-T Cell Therapy
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor.
- Trial name
- NCT04429451
- Testing
- 4SCAR-PSMA T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.
- Trial name
- NCT06862856
- Testing
- Positron Emission Tomography (PET)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Prostate CA
Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study
The prostate specific antigen (PSA) blood test can help diagnose prostate problems, including cancer. The prostate is an organ in the pelvis. It is found in cisgender men, transgender (trans) women and some non-binary people.
- Trial name
- TransPRIDE (NCT06987045)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Prostate Cancer, Adenocarcinoma
Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer
To evaluate the role of biparametric MRI and image-fusion targeted biopsies for the detection of prostate cancer. To determine whether biparametric MRI (bpMRI) could be recommended as an alternative to multiparametric MRI (mpMRI)…
- Conditions
- Prostate Cancer, Adenocarcinoma, Prostatic Neoplasms, Prostatic Diseases
- Trial name
- IP7-PACIFIC (NCT05574647)
- Testing
- bpMRI, Image-Fusion targeted and systematic Biopsy
- Where
- 15 sites in United Kingdom
- Volunteers
- 3,600 people
- Sponsor
- Imperial College London